Ignite Creation Date:
2025-12-25 @ 2:39 AM
Ignite Modification Date:
2026-03-03 @ 7:47 PM
Study NCT ID:
NCT03312634
Status:
COMPLETED
Last Update Posted:
2023-11-29
First Post:
2017-10-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Sponsor:
Clementia Pharmaceuticals Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Fibrodysplasia Ossificans Progressiva | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Interventional study | View |
| None | Clinical trial phase 3 | View |
| None | Efficacy and safety | View |
| None | Heterotopic ossification | View |
| None | Flare-up | View |
| None | Palovarotene | View |
| None | Retinoic acid receptor agonist | View |
| None | Retinoic acid receptor gamma agonist | View |
| None | Clementia | View |
| None | Myositis Ossificans Progressiva | View |
| None | Munchmeyer's Disease | View |
| None | FOP | View |
| None | FOP variants | View |